Ameriprise Financial Inc. Sells 44,563 Shares of Enovis Co. (NYSE:ENOV)

Ameriprise Financial Inc. decreased its position in Enovis Co. (NYSE:ENOV - Free Report) by 47.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,524 shares of the company's stock after selling 44,563 shares during the quarter. Ameriprise Financial Inc. owned 0.09% of Enovis worth $2,173,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd purchased a new position in shares of Enovis in the 4th quarter worth approximately $29,000. Quadrant Capital Group LLC boosted its holdings in shares of Enovis by 53.0% in the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after purchasing an additional 239 shares during the period. Quarry LP boosted its holdings in shares of Enovis by 506.1% in the 4th quarter. Quarry LP now owns 897 shares of the company's stock worth $39,000 after purchasing an additional 749 shares during the period. Sterling Capital Management LLC boosted its holdings in shares of Enovis by 56.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,259 shares of the company's stock worth $143,000 after purchasing an additional 1,173 shares during the period. Finally, Legacy Capital Wealth Partners LLC purchased a new position in shares of Enovis in the 4th quarter worth approximately $228,000. Institutional investors own 98.45% of the company's stock.

Enovis Trading Down 2.3%

ENOV traded down $0.73 during trading hours on Friday, reaching $31.32. 974,234 shares of the company's stock traded hands, compared to its average volume of 796,849. The firm has a 50-day moving average price of $34.00 and a 200 day moving average price of $40.55. Enovis Co. has a 52-week low of $29.32 and a 52-week high of $51.00. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $1.79 billion, a PE ratio of -14.30 and a beta of 1.79.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.07. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $558.83 million during the quarter, compared to analysts' expectations of $558.80 million. During the same quarter in the previous year, the business earned $0.50 EPS. Enovis's revenue was up 8.2% compared to the same quarter last year. As a group, sell-side analysts predict that Enovis Co. will post 2.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Needham & Company LLC dropped their target price on Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a report on Friday, May 9th. JMP Securities dropped their target price on Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Finally, Canaccord Genuity Group dropped their target price on Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $58.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.